Breast Cancer Staging: Is TNM Ready to Evolve?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Machine learning-derived prognostic signature integrating programmed cell death and mitochondrial function in renal clear cell carcinoma: identification of PIF1 as a novel target.Cancer immunology, immunotherapy : CII · 2025
   Article
2. Reclassifying TNM stage I/II colorectal cancer into two subgroups with different overall survival, tumor microenvironment, and response to immune checkpoint blockade treatment.Frontiers in genetics · 2022
   Article
3. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.Nature reviews. Cancer · 2020
   Review
4. Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0.Frontiers in psychiatry · 2018
   Review
5. Detection and quantitative analysis of tumor-associated tertiary lymphoid structures.Journal of Zhejiang University. Science. B
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as